Institute of Otorhinolaryngology, Policlinico Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.
Head Neck. 2013 Apr;35(4):554-61. doi: 10.1002/hed.22994. Epub 2012 Apr 12.
Functional outcome and quality of life (QOL) have become relevant endpoints in the field of laryngeal oncology, leading to the emergence of organ-preserving strategies.
The medical records of 166 patients with advanced (stages III and IV) laryngeal squamous cell carcinoma (SCC) who were treated with a total laryngectomy, radiochemotherapy, or cricohyoidopexy (CHP) were reviewed.
In the whole series, no statistically significant differences among the 3 treatment arms with respect to the overall survival (OS) and disease-specific survival (DSS) rates were observed. The organ-preservation rate was 45% for radiotherapy and 76.7% for CHP (p = .0002). Among the cT4a cases, a longer survival was observed for the patients treated with total laryngectomy (3 yr-OS = 78% vs 68% for CHP and 54% for radiochemotherapy, p = .031).
In advanced laryngeal SCC, CHP shows survival rates comparable to those of radiochemotherapy and a higher larynx-preservation rate, although it may not replace radiochemotherapy because it can be recommended only in selected cases.
功能结果和生活质量（QOL）已成为喉癌领域的相关终点，导致出现了保留器官的治疗策略。
回顾了 166 例接受全喉切除术、放化疗或环舌骨固定术（CHP）治疗的晚期（III 期和 IV 期）喉鳞状细胞癌（SCC）患者的病历。
在整个系列中，3 种治疗组之间在总生存率（OS）和疾病特异性生存率（DSS）方面没有统计学上的显著差异。放疗的保器官率为 45%，CHP 为 76.7%（p =.0002）。在 cT4a 病例中，接受全喉切除术的患者的生存率更高（3 年 OS = 78%，与 CHP 相比为 68%，与放化疗相比为 54%，p =.031）。
在晚期喉 SCC 中，CHP 显示出与放化疗相当的生存率和更高的喉保留率，尽管它可能无法替代放化疗，因为它只能在选定的病例中推荐。
